Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Ovarian Neoplasms

  Free Subscription


Articles published in Obstet Gynecol

Retrieve available abstracts of 40 articles:
HTML format
Text format



Single Articles


    September 2017
  1. LIPPITT MH, Fairbairn MG, Matsuno R, Stone RL, et al
    Outcomes Associated With a Five-Point Surgical Site Infection Prevention Bundle in Women Undergoing Surgery for Ovarian Cancer.
    Obstet Gynecol. 2017 Sep 5. doi: 10.1097/AOG.0000000000002213.
    PubMed     Text format     Abstract available



  2. Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.
    Obstet Gynecol. 2017;130:e146-e149.
    PubMed     Text format     Abstract available



  3. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome.
    Obstet Gynecol. 2017;130:e110-e126.
    PubMed     Text format     Abstract available



  4. Committee Opinion No. 716 Summary: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk.
    Obstet Gynecol. 2017;130:664-665.
    PubMed     Text format     Abstract available



  5. Practice Bulletin No. 182 Summary: Hereditary Breast and Ovarian Cancer Syndrome.
    Obstet Gynecol. 2017;130:657-659.
    PubMed     Text format     Abstract available


    August 2017
  6. WRIGHT JD, Chen L, Hou JY, Burke WM, et al
    Association of Hospital Volume and Quality of Care With Survival for Ovarian Cancer.
    Obstet Gynecol. 2017 Aug 4. doi: 10.1097/AOG.0000000000002164.
    PubMed     Text format     Abstract available


  7. MARTINELLI F, Ditto A, Bogani G, Raspagliesi F, et al
    Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
    Obstet Gynecol. 2017;130:469-470.
    PubMed     Text format    


    July 2017
  8. SPENCER RJ, Hacker KE, Griggs JJ, Rice LW, et al
    Ninety-Day Mortality as a Reporting Parameter for High-Grade Serous Ovarian Cancer Cytoreduction Surgery.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002140.
    PubMed     Text format     Abstract available


  9. MATSUO K, Machida H, Stone RL, Soliman PT, et al
    Risk of Subsequent Ovarian Cancer After Ovarian Conservation in Young Women With Stage I Endometrioid Endometrial Cancer.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002142.
    PubMed     Text format     Abstract available


  10. CORY L, Latif N, Brensinger C, Zhang X, et al
    Readmission After Gynecologic Surgery: A Comparison of Procedures for Benign and Malignant Indications.
    Obstet Gynecol. 2017 Jul 7. doi: 10.1097/AOG.0000000000002141.
    PubMed     Text format     Abstract available


    June 2017
  11. MELAMED A, Rizzo AE, Nitecki R, Gockley AA, et al
    All-Cause Mortality After Fertility-Sparing Surgery for Stage I Epithelial Ovarian Cancer.
    Obstet Gynecol. 2017 Jun 6. doi: 10.1097/AOG.0000000000002102.
    PubMed     Text format     Abstract available


    May 2017
  12. GRECO PS, Bazzi AA, McLean K, Reynolds RK, et al
    Incidence and Timing of Thromboembolic Events in Patients With Ovarian Cancer Undergoing Neoadjuvant Chemotherapy.
    Obstet Gynecol. 2017 May 5. doi: 10.1097/AOG.0000000000001980.
    PubMed     Text format     Abstract available


  13. FAJAU-PREVOT C, Le Gac YT, Chevreau C, Cohade C, et al
    Ovarian Mucinous Cystadenoma After Ovarian Graft.
    Obstet Gynecol. 2017 May 5. doi: 10.1097/AOG.0000000000001990.
    PubMed     Text format     Abstract available


    April 2017
  14. MELAMED A, Nitecki R, Boruta DM 2nd, Del Carmen MG, et al
    Laparoscopy Compared With Laparotomy for Debulking Ovarian Cancer After Neoadjuvant Chemotherapy.
    Obstet Gynecol. 2017 Apr 4. doi: 10.1097/AOG.0000000000001851.
    PubMed     Text format     Abstract available


    February 2017
  15. GOCKLEY A, Melamed A, Bregar AJ, Clemmer JT, et al
    Outcomes of Women With High-Grade and Low-Grade Advanced-Stage Serous Epithelial Ovarian Cancer.
    Obstet Gynecol. 2017 Feb 6. doi: 10.1097/AOG.0000000000001867.
    PubMed     Text format     Abstract available


    September 2016
  16. MATSUO K, Machida H, Shoupe D, Melamed A, et al
    Ovarian Conservation and Overall Survival in Young Women With Early-Stage Low-Grade Endometrial Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    August 2016
  17. EVANS EC, Matteson KA, Orejuela FJ, Alperin M, et al
    Salpingo-oophorectomy at the Time of Benign Hysterectomy: A Systematic Review.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    May 2016
  18. WRIGHT JD, Hou JY, Burke WM, Tergas AI, et al
    Utilization and Toxicity of Alternative Delivery Methods of Adjuvant Chemotherapy for Ovarian Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  19. CHATTERJEE S, Chen L, Tergas AI, Burke WM, et al
    Utilization and Outcomes of Chemotherapy in Women With Intermediate-Risk, Early-Stage Ovarian Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  20. MOTOHARA T, Fujimoto K, Tayama S, Narantuya D, et al
    CD44 Variant 6 as a Predictive Biomarker for Distant Metastasis in Patients With Epithelial Ovarian Cancer.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  21. HARMSEN MG, IntHout J, Arts-de Jong M, Hoogerbrugge N, et al
    Salpingectomy With Delayed Oophorectomy in BRCA1/2 Mutation Carriers: Estimating Ovarian Cancer Risk.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


  22. CHAPPELL NP, Miller C, Barnett J, Fielden A, et al
    Is FDA Approved Bevacizumab Cost-Effective in the Setting of Platinum-Resistant Recurrent Ovarian Cancer? [18].
    Obstet Gynecol. 2016;127 Suppl 1:6S-7S.
    PubMed     Text format     Abstract available


  23. GOTIMER KF, Bondoc C, Chalas E, Villella JA, et al
    Self Reported Quality of Life Among Patients Who Have Undergone Outpatient IP Chemotherapy for Ovarian Cancer [11].
    Obstet Gynecol. 2016;127 Suppl 1:4S.
    PubMed     Text format     Abstract available


    April 2016
  24. POWER L, Lefas G, Lambert P, Kim D, et al
    Hormone Use After Nonserous Epithelial Ovarian Cancer: Overall and Disease-Free Survival.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    March 2016
  25. SCHORGE JO
    What Is New in Prevention of Ovarian Cancer?: Best Articles From the Past Year.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    February 2016
  26. WRIGHT JD, Tergas AI, Hou JY, Burke WM, et al
    Trends in Periodic Surveillance Testing for Early-Stage Uterine Cancer Survivors.
    Obstet Gynecol. 2016.
    PubMed     Text format     Abstract available


    December 2015
  27. LIN JJ, Egorova N, Franco R, Prasad-Hayes M, et al
    Ovarian Cancer Treatment and Survival Trends Among Women Older Than 65 Years of Age in the United States, 1995-2008.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  28. WRIGHT JD, Huang Y, Burke WM, Tergas AI, et al
    Influence of Lymphadenectomy on Survival for Early-Stage Endometrial Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  29. WRIGHT JD, Jorge S, Tergas AI, Hou JY, et al
    Utilization and Outcomes of Ovarian Conservation in Premenopausal Women With Endometrial Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    November 2015
  30. BARBER EL, Boggess JF, Van Le L, Kim KH, et al
    Association of Preoperative Thrombocytosis and Leukocytosis With Postoperative Morbidity and Mortality Among Patients With Ovarian Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    October 2015
  31. ESSELEN KM, Vitonis A, Einarsson J, Muto MG, et al
    Health Care Disparities in Hysterectomy for Gynecologic Cancers: Data From the 2012 National Inpatient Sample.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  32. TEMKIN SM, Terplan M
    Trends in Relative Survival for Ovarian Cancer From 1975-2011.
    Obstet Gynecol. 2015;126:898.
    PubMed     Text format    


  33. WRIGHT JD, Chen L, Hershman DL
    In Reply.
    Obstet Gynecol. 2015;126:898-9.
    PubMed     Text format    


    September 2015
  34. MELAMED A, Rauh-Hain JA, Clemmer JT, Diver EJ, et al
    Changing Trends in Lymphadenectomy for Endometrioid Adenocarcinoma of the Endometrium.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    July 2015
  35. CRESS RD, Chen YS, Morris CR, Petersen M, et al
    Characteristics of Long-Term Survivors of Epithelial Ovarian Cancer.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


  36. PRAT J
    Staging Classification for Cancer of the Ovary, Fallopian Tube, and Peritoneum: Abridged Republication of Guidelines From the International Federation of Gynecology and Obstetrics (FIGO).
    Obstet Gynecol. 2015;126:171-4.
    PubMed     Text format    


    June 2015
  37. WRIGHT JD, Chen L, Tergas AI, Patankar S, et al
    Trends in relative survival for ovarian cancer from 1975 to 2011.
    Obstet Gynecol. 2015;125:1345-52.
    PubMed     Text format     Abstract available


  38. RAUH-HAIN JA, Hariton E, Clemmer J, Clark RM, et al
    Incidence and effects on mortality of venous thromboembolism in elderly women with endometrial cancer.
    Obstet Gynecol. 2015;125:1362-70.
    PubMed     Text format     Abstract available


    April 2015
  39. YEH KE, Marcus PS, Fong TL
    Paraneoplastic Cholestasis Associated With Ovarian Dysgerminoma.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


    January 2015
  40. JANCO JM, Gloviczki P, Friese JL, Cliby WA, et al
    Lymphatic Mapping and Ligation for Persistent Ascites After Surgery for Gynecologic Malignancy.
    Obstet Gynecol. 2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Ovarian Neoplasms is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: